Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive
HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.
New drug can help activate liver regeneration and repair in end-stage liver disease